Teach me valproate in detail…history, pharmacokinetics dynamics, moa, half life, sideeffects..common serious rare, formulations, dosages, combinations ,guidelines of use,..nice and cpg, contraindications, interactions…everything…
Reading File
Finding Sources
Finding Sources
Searching the Web
valproate valproic acid complete pharmacology guidelines NICE CPG 2024 2025
Searching PubMed
valproate epilepsy guidelines
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have rich, comprehensive material from multiple authoritative textbooks. Let me compile the complete answer.
Valproate - Complete Pharmacology Reference
1. History
Valproic acid (n-dipropylacetic acid) was synthesized in 1882 by Burton as an organic solvent and used industrially for decades. Its anticonvulsant properties were discovered serendipitously in 1963 by Pierre Eymard and Henri Meunier in France - it was being used as a vehicle/solvent to dissolve other compounds being screened for antiseizure activity, and the researchers noticed that every compound dissolved in it appeared to have anticonvulsant activity. Valproic acid itself was the active agent. It was approved in France in 1967 and reached the US market in 1978 (FDA approval). It subsequently expanded into bipolar disorder (divalproex/Depakote approved for mania by the FDA in 1995) and migraine prophylaxis.
2. Chemistry and Forms
Valproate is a simple branched-chain carboxylic acid (n-dipropylacetic acid). It is available in three chemical forms:
| Form | Notes |
|---|---|
| Valproic acid | Free acid form |
| Sodium valproate | Sodium salt; licensed for epilepsy |
| Valproate semisodium (divalproex) | 1:1 molar combination of sodium valproate + valproic acid; licensed for acute mania; released as valproate ion in the GI tract |
All three are metabolized to the same active species - valproate ion - so pharmacological activity is essentially equivalent, with minor bioavailability differences.
Straight-chain carboxylic acids have minimal anticonvulsant activity; branched-chain structure is essential. Increasing carbon chain length beyond 8-9 introduces sedative properties.
3. Mechanism of Action (MOA)
Valproate has a complex, multi-modal mechanism that is not fully understood, which also explains its broad-spectrum activity:
3a. Sodium Channel Blockade
- Inhibits sustained repetitive firing by prolonging recovery of voltage-gated Na+ channels from inactivation - similar to phenytoin and carbamazepine
- This is the primary mechanism against focal and tonic-clonic seizures
3b. T-type Calcium Channel Blockade
- Reduces T-type Ca2+ currents at slightly higher therapeutic concentrations
- Similar to ethosuximide's effect in thalamic neurons
- Contributes to efficacy against absence seizures
3c. GABAergic Enhancement
- Inhibits GABA transaminase (GABA-T) - the enzyme that degrades GABA
- Inhibits succinic semialdehyde dehydrogenase (another GABA-degrading enzyme)
- Stimulates glutamic acid decarboxylase (GAD) - the GABA synthetic enzyme
- Net effect: increases brain GABA levels
- Note: valproate does NOT directly act at GABA receptors
3d. Histone Deacetylase (HDAC) Inhibition
- Potent inhibitor of HDAC enzymes
- Modulates gene expression through epigenetic mechanisms
- May contribute to antiseizure, mood-stabilizing, and emerging anticancer effects
- Also alters expression of genes involved in transcription regulation, cytoskeletal modifications, and ion homeostasis
3e. Additional Mechanisms (Mood Stabilization)
- Reduces arachidonic acid turnover
- Activates the ERK (extracellular signal-regulated kinase) pathway - alters synaptic plasticity
- Interferes with intracellular signaling
- Promotes BDNF (brain-derived neurotrophic factor) expression
- Reduces protein kinase C (PKC) levels
- Depletes inositol (shared with lithium)
This multiplicity of mechanisms explains why valproate works across seizure types, bipolar disorder, and migraine.
(Sources: Goodman & Gilman's, Katzung, Maudsley Guidelines 15th ed.)
4. Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | Nearly 100% after oral administration |
| Tmax | 1-4 hours (delayed by enteric-coated forms or food; may extend to several hours) |
| Volume of distribution (Vd) | ~0.2 L/kg (small - largely confined to extracellular fluid + plasma) |
| Protein binding | ~90% bound to plasma albumin at low concentrations; binding becomes saturated at higher concentrations, increasing free fraction |
| Half-life (t½) | Approximately 9-16 hours (average ~15 h); reduced to 6-12 h in patients on enzyme-inducing AEDs (phenytoin, carbamazepine, phenobarbital) |
| Metabolism | 95% hepatic; mainly via UGT enzymes and β-oxidation; minor contribution from CYP2C9 and CYP2C19 |
| Excretion | <5% excreted unchanged in urine |
| Active metabolites | 2-propyl-2-pentenoic acid (2-en-valproate) and 2-propyl-4-pentenoic acid - near equipotent antiseizure activity; 2-en-valproate accumulates in plasma and brain |
| CSF penetration | Concentrations suggest equilibration with free drug; carrier-mediated transport both into and out of CSF |
| Pharmacokinetics model | Three-compartmental model; protein binding saturation makes it nonlinear at therapeutic levels |
Protein Binding Saturation - Clinical Implication
Because albumin binding saturates through the therapeutic range, increasing the dose leads to disproportionate increases in free drug concentration. This matters especially when combining with other highly protein-bound drugs.
(Sources: Goodman & Gilman's, Maudsley 15th ed.)
5. Therapeutic Drug Monitoring
| Parameter | Value |
|---|---|
| Therapeutic serum level | 50-100 μg/mL (mg/L) for epilepsy |
| Apparent threshold | ~30-50 μg/mL (where albumin binding begins to saturate) |
| Toxicity level | Generally >100-150 μg/mL |
| Correlation | Poor correlation between plasma concentration and efficacy; more useful for adherence and toxicity monitoring than titration |
| In bipolar disorder | Target serum level 50-100 μg/mL, but clinical response guides dosing; thrombocytopenia more likely at levels ≥110 μg/mL (women) and ≥135 μg/mL (men) |
| Where hypoalbuminaemia exists | Free valproate levels should be measured |
6. Formulations
Oral Solid Forms
| Formulation | Notes |
|---|---|
| Valproic acid capsules (e.g., Depakene, Convulex) | 250 mg caps; most likely to cause GI side effects |
| Sodium valproate enteric-coated tablets (Epilim) | Reduces GI irritation |
| Divalproex sodium delayed-release tablets (Depakote) | Twice-daily dosing; better GI tolerability |
| Divalproex sodium extended-release (Depakote ER) | Once-daily dosing possible |
| Sodium valproate controlled-release (Epilim Chrono) | Can be given once daily; preferred in UK |
| Divalproex sodium sprinkle capsules | Contents can be sprinkled on food; useful in children/dysphagics |
Liquid/Other
| Formulation | Notes |
|---|---|
| Valproic acid oral solution (Depakene syrup) | 250 mg/5 mL; can be used rectally (diluted 1:1 with water) |
| Valproate sodium injection (IV, previously Depacon) | 100 mg/mL; for use when oral route unavailable; same daily dose divided Q6h IV |
Brands in UK include: Epilim, Depakote, Convulex, Episenta, Epival, Kentlim, Orlept, Syonell, Valpal, Belvo, Dyzantil, Epilim Chrono/Chronosphere.
Clinical risk: The large variety of formulations with different release characteristics creates significant risk for medication errors. Brand switching or formulation switching is NOT recommended without specialist review.
7. Dosages
Epilepsy (Adults)
- Starting dose: 600 mg/day in 2-3 divided doses (or 10-15 mg/kg/day)
- Increase: 150-300 mg every 3 days (slower titration if needed)
- Maintenance: 1,000-2,000 mg/day (20-30 mg/kg/day)
- Maximum: 2,500 mg/day (up to 60 mg/kg/day)
Epilepsy (Children >20 kg)
- Starting: 400 mg/day (irrespective of weight)
- Maintenance: 20-30 mg/kg/day
- Maximum: Up to 60 mg/kg/day (up to 100 mg/kg/day in children on enzyme inducers)
Bipolar Disorder / Mania (Adults)
- Oral loading: 20-30 mg/kg/day (loading strategy for acute mania)
- Starting (standard titration): 750 mg/day in divided doses
- Rapid titration target: 1,500-2,000 mg/day over a few days
- Recommended maximum: 60 mg/kg/day
- Divalproex sodium ER: same total daily dose as IR, given once daily
Migraine Prophylaxis (Adults)
- Start: 500 mg/day in 2 divided doses (250 mg BID)
- Increase gradually to: 1,000 mg/day maximum
- Divalproex ER: once daily
IV Dosing
- Use the same total daily oral dose divided Q6 hours
- Convert back to oral as soon as possible
Rectal (Emergency, limited data)
- Load: 20 mg/kg/dose (syrup diluted 1:1 with water, PR retention enema)
- Maintenance: 10-15 mg/kg/dose Q8h
8. Indications (Licensed and Off-Label)
Licensed
- All forms of epilepsy (focal, generalized including absence, myoclonic, tonic-clonic)
- Juvenile myoclonic epilepsy (JME) - drug of choice
- Acute mania (divalproex/semisodium licensed in most countries)
- Bipolar disorder maintenance (some formulations)
- Migraine prophylaxis (divalproex ER)
Off-Label (evidence varies)
- Bipolar depression (small-to-medium effect size from meta-analyses)
- Rapid-cycling bipolar (limited utility)
- Schizoaffective disorder
- Aggression/behavioral disturbance in psychiatric disorders
- Prevention of atypical antipsychotic-induced seizures
- Status epilepticus (IV divalproex)
- Neuropathic pain
- PTSD (limited evidence)
- Adjunctive in certain cancers (emerging research - HDAC inhibition)
9. Side Effects
Common (>5-10%)
| Side Effect | Notes |
|---|---|
| Nausea, vomiting, dyspepsia, diarrhea | Most common; worst in first month; less with enteric-coated/ER forms |
| Sedation, fatigue | Dose-dependent |
| Tremor | Often dose-dependent; may respond to propranolol or gabapentin |
| Weight gain | Common especially long-term; requires dietary monitoring |
| Alopecia (hair loss) | 5-10% of patients; sometimes reversible; zinc + selenium supplements may help |
| Elevated liver transaminases | 5-40% of patients; usually asymptomatic and transient; up to 3x ULN common |
| Thrombocytopenia | More common at high doses; prolongs bleeding time |
Serious (1-5%)
| Side Effect | Notes |
|---|---|
| Hepatotoxicity | Elevated LFTs in up to 40%; dose-dependent |
| Hyperammonemia | Even with normal LFTs; can cause encephalopathy |
| Teratogenicity | Neural tube defects 1-4% (spina bifida, predominantly lumbosacral); cardiac defects; cleft palate; hypospadias; polydactyly; cognitive impairment in offspring; autism risk |
| Pancreatitis | Usually in first 6 months; can be fatal |
| Polycystic ovarian syndrome (PCOS) | Especially in adolescent/young women; menstrual irregularities, hirsutism, insulin resistance |
| Coagulopathy | Platelet dysfunction and thrombocytopenia |
| Cognitive effects in exposed fetuses | Dose-dependent lower IQ at age 6 vs. other AEDs; autistic spectrum disorder risk |
Rare but Potentially Fatal
| Side Effect | Notes |
|---|---|
| Fulminant hepatic failure | Microvesicular steatosis; NO inflammation (NOT allergic/idiosyncratic reaction); highest risk: children <2 years on polytherapy with other medical conditions; risk approaches zero in patients >10 years on monotherapy |
| Acute pancreatitis | Rare; can be fatal |
| Hyperammonemic encephalopathy | Especially with topiramate co-administration |
| Aplastic anemia | Extremely rare |
| Stevens-Johnson syndrome | Very rare |
Notable Metabolic Effects
- Hyponatremia at high doses (>1,000 mg/day) - possible SIADH mechanism; reversible with dose reduction
- Hypothermia - especially with topiramate combination
10. Drug Interactions
Valproate is both a substrate and a potent inhibitor of several metabolic pathways.
Valproate as an INHIBITOR (increases levels of other drugs)
| Drug | Mechanism | Clinical consequence |
|---|---|---|
| Lamotrigine | Inhibits UGT glucuronidation | Doubles lamotrigine levels - must halve lamotrigine dose |
| Phenobarbital | Inhibits CYP2C9 | Phenobarbital toxicity (sedation) |
| Phenytoin | Inhibits CYP2C9 + displaces from albumin | Phenytoin toxicity even with unchanged total levels (free fraction rises) |
| Lorazepam | Inhibits UGT | Increased sedation |
| Warfarin | Displaces from albumin | Higher free warfarin; bleeding risk |
| TCAs (esp. clomipramine) | Inhibits glucuronidation | TCA toxicity |
| Quetiapine | Inhibits glucuronidation | Increased quetiapine levels |
| Carbamazepine | Displaces from protein | Carbamazepine toxicity; need dose reduction of CBZ |
Drugs that AFFECT valproate levels
| Drug | Effect | Mechanism |
|---|---|---|
| Aspirin (≥300 mg) | Increases free valproate | Displaces from albumin AND inhibits valproate metabolism |
| Carbamazepine | Decreases valproate levels | CYP induction (3A4/2C9); also increases toxic 4-en-valproate metabolite |
| Phenytoin | Decreases valproate levels | CYP induction |
| Phenobarbital | Decreases valproate levels | CYP induction |
| Erythromycin | Increases valproate | CYP inhibition |
| Fluoxetine | Increases valproate | CYP inhibition |
| Cimetidine | Increases valproate | CYP inhibition |
Pharmacodynamic Interactions
| Interaction | Effect |
|---|---|
| Topiramate + valproate | Hyperammonemia and encephalopathy (even with normal LFTs), hypothermia |
| Clonazepam + valproate | Rare risk of absence status epilepticus |
| Antipsychotics | Seizure threshold lowering antagonizes valproate anticonvulsant effect |
| Clozapine/olanzapine + valproate | Additive weight gain; valproate may lower olanzapine levels |
| CNS depressants | Additive sedation |
11. Contraindications
Absolute
- Hepatic disease (any significant liver dysfunction)
- Personal or family history of severe hepatotoxicity related to valproate
- Mitochondrial disorders with mutations in DNA polymerase gamma (POLG gene) - e.g., Alpers-Huttenlocher syndrome (high risk of acute liver failure)
- Urea cycle disorders (UCD) - e.g., ornithine transcarbamylase (OTC) deficiency - risk of hyperammonemic encephalopathy
- Porphyria
- Women of childbearing potential (in many countries/conditions - see below)
- Children <2 years of age (high risk of fatal hepatotoxicity, especially on polytherapy)
Condition-Specific
- Contraindicated for migraine prophylaxis in pregnancy
- Known hypersensitivity to valproate
12. Special Populations
Pregnancy - CRITICAL WARNINGS
This is the most important safety concern with valproate.
Teratogenic risks:
- Neural tube defects: 1-4% risk in first trimester (predominantly lumbosacral spina bifida, not anencephaly); occurs at 17-30 days after conception; dose-dependent
- Cardiac defects, cleft palate, hypospadias, polydactyly - increased risk vs. general population
- Neurodevelopmental harm: Lower IQ in exposed children (by ~7-10 points at age 6 vs. lamotrigine-exposed); autistic spectrum disorder risk increased
- Fetal growth restriction, neonatal withdrawal, hypoglycemia, reduced fibrinogen
UK Valproate Pregnancy Prevention Programme (PPP):
- Valproate is contraindicated in women of childbearing potential (epilepsy or bipolar) UNLESS no suitable alternative AND conditions of the PPP are met
- Annual review by a specialist is mandatory
- Two forms of effective contraception required
- MHRA 2024: New regulatory measures - all new patients starting valproate must be reviewed by two specialists
- MHRA Feb 2025: Two-specialist review requirement applies to initiating treatment in ALL patients, including males
- MHRA Sept 2024: Men and their partners should use effective contraception - pooled data showed adjusted HR ~1.5 for neurodevelopmental disorders in children born to fathers taking valproate
Folic acid: All women of childbearing potential on valproate should take folic acid 1-5 mg/day - reduces (but does NOT eliminate) risk.
Breastfeeding: Infant serum levels ~1-10% of maternal; not contraindicated in nursing mothers.
Children (<2 years)
High risk of fatal hepatotoxicity; avoid if at all possible.
Renal Impairment
Minimal dose adjustment needed for most patients; however, hypoalbuminaemia in renal disease increases free fraction.
Hepatic Impairment
Contraindicated - valproate is 95% hepatically metabolized.
13. Combination Use
Epilepsy Combinations
- Valproate + lamotrigine: Highly synergistic; however, valproate doubles lamotrigine levels - lamotrigine must be started at half the usual dose and titrated very slowly (risk of rash/Stevens-Johnson)
- Valproate + ethosuximide: Synergistic for absence seizures
- Valproate + levetiracetam: Generally safe; no clinically significant pharmacokinetic interactions
- Valproate + carbamazepine: Valproate displaces CBZ from protein binding; CBZ dose reduction needed; also increases production of toxic CBZ-epoxide metabolite
- AVOID valproate + topiramate: Hyperammonemia/encephalopathy risk
- Valproate + clonazepam: Use with caution - rare risk of absence status epilepticus
Bipolar Disorder Combinations
- Valproate + lithium: Many clinicians use this combination for partial responders; generally well tolerated; blood level monitoring of both required
- Valproate + carbamazepine: Reports of efficacy in refractory rapid-cycling; complex pharmacokinetics require monitoring; CBZ dose reduction required
- Valproate + antipsychotics (e.g., olanzapine, risperidone): Common and generally well-tolerated combination for acute mania; additive weight gain; olanzapine levels may be lowered; quetiapine levels may rise
- Valproate + lamotrigine: Used for bipolar prophylaxis; lamotrigine dose halved
14. Guidelines
UK - NICE Guideline NG217 (Epilepsies, April 2022, updated January 2025)
- Valproate remains first-line for generalised epilepsies (including JME, childhood absence, tonic-clonic)
- NOT recommended as first-line for women of childbearing potential; alternatives preferred (lamotrigine, levetiracetam)
- If valproate used in women: mandatory specialist review, PPP compliance, documented discussion of risks
- Baseline FBC, LFTs, and weight/BMI before starting
- Repeat FBC and LFTs at 6 months; ongoing BMI monitoring
UK - NICE Guideline NG185 (Bipolar Disorder, updated 2023)
- Valproate should NOT be used in women of childbearing age with bipolar disorder
- Not first-line in women; alternatives include lithium, quetiapine, olanzapine, lamotrigine
- When used in men: routine monitoring, annual specialist review
MHRA Safety Measures (UK, 2023-2025)
- National Patient Safety Alert (November 2023): NHS-wide programme to eliminate harm
- February 2024: New regulatory oversight of prescribing for new patients and existing female patients
- September 2024: Men and partners must use effective contraception
- February 2025: Two-specialist review required before initiating valproate in any new patient
AAN/AES/SMFM Practice Guideline (2024 - PMID 38748979)
- Confirms valproate has the highest teratogenic risk among ASMs
- Recommends against use in pregnancy unless no suitable alternative
- Comprehensive pre-conception counselling mandatory
Clinical Monitoring Requirements (Summary)
| Timing | Tests |
|---|---|
| Pre-treatment | FBC, LFTs, U&E, weight/BMI; pregnancy test in women; discuss contraception |
| 6 months | FBC, LFTs; weight/BMI |
| Ongoing | Annual review by specialist; LFTs, FBC if symptomatic; serum levels if indicated |
| High-dose or symptomatic | Albumin, clotting, amylase (if pancreatitis suspected), ammonia (if encephalopathy) |
15. Summary Pharmacology Table
| Property | Value |
|---|---|
| Class | Branched-chain fatty acid / anticonvulsant / mood stabilizer |
| MOA | Na+ channel blockade, T-Ca2+ blockade, GABA-T inhibition, HDAC inhibition |
| Oral bioavailability | ~100% |
| Protein binding | ~90% (saturable) |
| Vd | ~0.2 L/kg |
| t½ | 9-16 hours (average ~15 h) |
| Metabolism | Hepatic - UGT, β-oxidation, minor CYP2C9/2C19 |
| Excretion | <5% renal unchanged |
| Therapeutic level | 50-100 μg/mL |
| Enzyme interaction | Inhibits CYP2C9, UGT, epoxide hydrolase |
| Key contraindications | Liver disease, POLG mutations, UCD, women of childbearing potential |
| Pregnancy category | X (for most indications); absolute teratogen |
Recent Evidence Update (2024-2025)
- MHRA Sept 2024 confirmed paternal valproate exposure carries a ~1.5x increased risk of neurodevelopmental disorders in offspring (adjusted HR 1.50, 95% CI 1.09-2.07) based on meta-analysis of pooled retrospective observational data - a much smaller risk than maternal exposure (up to 30-40%) but sufficient to warrant contraception advice for men.
- AAN/AES Practice Guideline 2024 (PMID 38748979) provides updated guidance on teratogenesis and perinatal outcomes for all antiseizure medications, confirming valproate's highest teratogenic profile.
- Maudsley 15th edition (2024) notes that valproate is less effective than lithium and several antipsychotics for acute mania in network meta-analyses, but remains a useful second-line or combination agent.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Katzung's Basic & Clinical Pharmacology 16th ed.; Lippincott Illustrated Reviews: Pharmacology; Maudsley Prescribing Guidelines in Psychiatry 15th ed.; Kaplan & Sadock's Synopsis of Psychiatry; Harriet Lane Handbook 23rd ed.; Creasy & Resnik's Maternal-Fetal Medicine; NICE NG217 (2022/2025); MHRA Drug Safety Updates 2023-2025; AAN/AES Practice Guideline 2024.
This is a shared conversation. Sign in to Orris to start your own chat.